On November 3, 2025 Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, reported that new clinical data will be presented in three oral and three poster sessions at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting from December 6-9 in Orlando, FL. The presentations will span its pipeline of investigational allogeneic T-cell immunotherapies for the treatment of multiple hematological malignancies including Orca-T, Orca-Q and the Orca-T and allogeneic CAR-T combination therapy, OrCAR-T.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our ongoing clinical evaluation of our pipeline across diverse patient populations, conditioning regimens and donor types underscores our commitment to advancing care for people with blood cancer," said Nate Fernhoff, Ph.D., co-founder and chief executive officer of Orca Bio. "We look forward to presenting new and expanded evidence from the pivotal Phase 3 study of our lead T-cell immunotherapy, Orca-T, along with data highlighting the potential of our next-generation candidate, Orca-Q, to enable treatment without GvHD prophylaxis. Overall, these findings mark meaningful progress toward our goal of delivering our high-precision approach to more patients who may benefit."
The ASH (Free ASH Whitepaper) abstracts are now available at www.hematology.org. Details of the Orca Bio oral and poster presentations follow:
Oral Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications
Title: Allogeneic HSC and Regulatory T cell (Orca-T) Engineered Cell Therapy Following Reduced Intensity Conditioning: Results of a Single Center Phase 1 Study
Abstract Number: 111
Date and Time: December 6, 2025 at 10:00 AM EST
Location: OCCC – Chapin Theater (320)
Oral Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant
Title: Superior Efficacy and Persistence of Orca-T-Allogeneic CAR19/22 Versus Autologous CAR19/22 in High-Risk Adult B-ALL
Abstract Number: 514
Date and Time: December 7, 2025 at 10:15 AM EST
Location: OCCC – Chapin Theater (320)
Oral Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond
Title: Preliminary Safety and Efficacy of Myeloablative Orca-Q with Tacrolimus or without GVHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
Abstract Number: 932
Date and Time: December 8, 2025 at 3:00 PM EST
Location: OCCC – W331
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I
Title: Orca-T Improves cGVHD-free Survival in Patients with a Broad Range of Demographic and Clinical Variables: Results of Randomized, Phase 3 Trial
Abstract Number: 2477
Date and Time: December 6, 2025 at 5:30 PM – 7:30 PM EST
Location: OCCC – West Halls B3-B4
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I
Title: Orca-T Demonstrates Favorable Quality of Life and Healthcare Resource Use Compared to Standard AlloHSCT plus Tac/MTX for GVHD Prevention in a Randomized Phase 3 Clinical Trial (Precision-T)
Abstract Number: 2473
Date and Time: December 6, 2025 at 5:30 PM – 7:30 PM EST
Location: OCCC – West Halls B3-B4
Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD
and Immune Reconstitution: Poster III
Title: Observational Comparison of Orca-T to Registry-Based Post-Transplant Cyclophosphamide Patients using Matched Unrelated Donor
Abstract Number: 6029
Date and Time: December 8, 2025 at 6:00 PM – 8:00 PM EST
Location: OCCC – West Halls B3-B4
About Orca-T
Orca-T is an investigational allogeneic T-cell immunotherapy under evaluation for the treatment of multiple hematologic malignancies including acute leukemias and myelodysplastic syndromes. Orca-T is composed of highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation for the prevention of graft versus host disease or death in patients eligible for hematopoietic stem cell transplant from the U.S. Food and Drug Administration (FDA). The Biologics License Application (BLA) for Orca-T is currently under Priority Review with the FDA with a PDUFA target action date of April 6, 2026.
About Orca-Q
Orca-Q is Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy under evaluation in clinical trials for the treatment of multiple hematologic malignancies, including in patients with haploidentical and mismatched donors. Orca-Q is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors and engineered by Orca Bio’s high-precision platform.
(Press release, Orca Bio, NOV 3, 2025, View Source;utm_medium=rss&utm_campaign=orca-bio-to-present-new-clinical-data-on-its-high-precision-cell-therapies-at-the-67th-american-society-of-hematology-annual-meeting [SID1234659271])